TGFB1 and cholestasis: An ARB (Candesartan) reduced liver fibrosis by suppressing collagen I and TGF-β1 expression as well as reducing hepatic stellate cell activation and the lipid peroxidation of proteins [56] through a therapeutic effect on cholestasis-induced liver fibrosis in rats.